Amgen, an American multinational biopharmaceutical firm based in Thousand Oaks, California and one of the largest independent global biotech companies in the world, has announced plans to create a new technology and innovation facility in Hyderabad, Telangana.
The Amgen India site will expedite digital capabilities for the entire company to further advance Amgen’s pipeline of medicines. The site has capacity for up to 3000 people and will be up and running by 2024.
Last Friday (August 09, 2024), A. Revanth Reddy, Chief Minister of Telangana, and Industries Minister Duddilla Sridhar Babu met Dr. David Reese and Mr. Som Chattopadhyay at Amgen’s R&D facility in San Francisco to reiterate their decision on selecting Hyderabad as their next innovation site.
Sridhar Babu IT & Industries Minister was thrilled with Amgen choosing Hyderabad for its base. This development underscores the success of creating a globally renowned life sciences ecosystem within Telangana.
He said that they would work together with the government to ensure that they succeed here. “This marks an exciting long-term partnership that heralds a healthier future.”
“It is indeed a major breakthrough and matter of pride for us that one of the biggest biotechnology firms worldwide selected Hyderabad as its first developmental facilities in Telangana,” said the Chief Minister.
“Hyderabad is being recognized more than ever as an epicenter for innovation and technology due to Amgen’s newest branch there. We are delighted to have global pioneers from within the biological industry joining us here. For our leading-edge technologists who are striving to make a significant difference in peoples’ lives across continents, this mission-driven focus by Amgen could not be more inspiring,” he added.
Roles available at the location
Hyderabad was chosen because it has top-tier expertise in medicine, life science & data science including AI which is growing at a rapid pace. The site has capacity for up to 3000 people and will be operational in Q4 2024, according to a statement by the CMO officials. Over time, the site will offer jobs that reinforce critical areas of Amgen’s operations like its AI, data science, life science and other additional global capabilities.
“Amgen has been preparing over the past ten years for this moment when biotechnology could truly converge with technology during an era of rapidly aging populations worldwide and thus allow us to work faster, with more confidence and efficiency – an incredibly exciting milestone,” said David M Reese, M.D., executive vice president and chief technology officer at Amgen.
Som Chattopadhyay has been named as national executive for India to head Amgen’s expanded presence in India. With almost 27k employees, it maintains operations in about 100 countries or territories globally.
